Moderna (NASDAQ:MRNA) announces that the first participants in each age cohort have been dosed in its Phase 2 clinical trial of its mRNA SARS-CoV-2 vaccine candidate mRNA-1273.
The study will enroll 600 healthy volunteers
across two age cohorts: 18-55 years old and 55+ years old. Each will
receive placebo or a 50 μg or a 100 μg dose of mRNA-1273 at both
vaccinations and will be followed for 12 months after the second shot.
The estimated primary completion date is March 2021.
https://seekingalpha.com/news/3578788-moderna-advancing-mid-stage-study-of-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.